Eli Lilly to acquire biotech firm in deal that could grow to more than $1.3B
Eli Lilly and Co. on Thursday announced that it has agreed to acquire Disarm Therapeutics, a private biotechnology company that is developing therapies that could be used to treat multiple sclerosis, glaucoma, Alzheimer’s disease and ALS.